Catalyst Calendar
Scope

Mon, Jun 29, 2026

1 updates

Fri, Jun 26, 2026

1 updates

Sun, May 31, 2026

1 updates
REPL
8:00 AM

Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

WOBURN, Mass., May 31, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today presented final first-in-human data for RP2 alone and in combination with nivolumab in patients with

Presentation / Abstract • Phase 1Oral presentation Sun, May 31, 2026, 9:12 AM CDTreplimune.com

Sat, May 30, 2026

1 updates
REPL
8:00 AM

Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

WOBURN, Mass., May 30, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today presented 3-year landmark overall survival data from the IGNYTE clinical trial of RP1 plus nivolumab in

Presentation / AbstractOral presentation Sat, May 30, 2026, 5:30 PM CDTreplimune.com

Fri, May 29, 2026

1 updates

Mon, Apr 27, 2026

1 updates